Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Meridian Bioscience’s Illumigene group A Streptococcus and group B Streptococcus tests have been recategorized under CLIA as moderate complexity. The new categorization of these tests allows the Illumigene platform to be available to all moderate-complexity labs in U.S. hospitals and clinics, allowing them to offer an accurate, rapid, simple molecular test for each of these pathogens.
Audit MicroControls’ MicroFD urine chemistry control, two levels, is intended to simulate human patient samples for monitoring the precision of laboratory testing procedures for urine chemistry assays, including amylase, calcium, chloride, creatinine, glucose, magnesium, microalbumin, microprotein, phosphorous, potassium, sodium, urea nitrogen, and uric acid.
Quest Diagnostics offers a clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
Randox Laboratories’ www.riqas.com allows users to discover the benefits offered by the Randox International Quality Assessment Scheme (RIQAS) and the advantages of implementing external quality assessment (EQA). The Web site displays information on well-designed, easy-to-navigate pages.
Bio/Data Corp.’s Collagen synthetic reactive peptide (SRP) is a synthetic type-1 collagen-like liquid polypeptide that self-assembles into a helix to form fibrils. Synthetic collagen may be useful in laboratories investigating platelet function and reactivity, platelet activation, and cellular analysis.
Qiagen offers a sample-to-result next-gen sequencing workflow designed to enable the routine use of NGS technology in areas such as clinical research and diagnostics. Qiagen’s NGS workflow is an ecosystem of products and services that offer automated processes from primary sample to digital result.
Eppendorf North America’s µCuvette G1.0 is for measuring small volumes of highly concentrated biomolecules, such as proteins and nucleic acids. Users can work easily with samples as small as 1.5 μL, without the need for a time-consuming dilution step. The μCuvette G1.0 expands the measuring range of the Eppendorf BioPhotometer and BioSpectrometer.
Roche has received FDA approval for its Cobas AmpliPrep/Cobas TaqMan HCV test, v2.0. The next-generation viral load test is for use in the management of patients with chronic hepatitis C virus infection. The test provides a novel dual-probe approach, for an extra layer of protection in detecting and quantifying the virus and is designed to accurately determine the amount of HCV RNA to assess a patient’s response to antiviral therapy.
Agilent Technologies’ SureSelect strand-specific RNA library preparation kit for whole transcriptome and targeted RNA sequencing allows researchers to prepare high-quality, strand-specific libraries for next-generation sequencing. The ability to gain strand-specific information from RNA sequencing experiments allows researchers to more easily discern overlapping transcripts and investigate antisense expression to better understand gene regulation.
Cerilliant offers certified spiking solutions for use in preparing T4-13C6, T3-13C6, and reverse T3-13C6 calibrators and controls for monitoring free and total thyroid hormone levels in serum or plasma by liquid chromatography-tandem mass spectrometry. These products offer clinical and endocrinology labs the full range of stable-labeled internal standards necessary for accurate quantitation of T4, T3, and reverse T3, using LC-MS/MS.
